Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?

GLOBOCAN 2020 estimated more than 19.3 million new cases, and about 10 million patients were deceased from cancer in 2020. Clinical manifestations showed that several growth factor receptors consisting of transmembrane and cytoplasmic tyrosine kinase (TK) domains play a vital role in cancer progress...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Raj Kumar Mongre, Chandra Bhushan Mishra, Arvind Kumar Shukla, Amresh Prakash, Samil Jung, Md Ashraf-Uz-Zaman, Myeong-Sok Lee
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	receptor tyrosine kinases drug resistance targeted therapy cancer mutation clinical trials Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/f7e4e2d1c4f14ffe8d65c0a026304786
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f7e4e2d1c4f14ffe8d65c0a026304786
record_format	dspace
spelling	oai:doaj.org-article:f7e4e2d1c4f14ffe8d65c0a0263047862021-11-11T17:07:44ZEmerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?10.3390/ijms2221116591422-00671661-6596https://doaj.org/article/f7e4e2d1c4f14ffe8d65c0a0263047862021-10-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/21/11659https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067GLOBOCAN 2020 estimated more than 19.3 million new cases, and about 10 million patients were deceased from cancer in 2020. Clinical manifestations showed that several growth factor receptors consisting of transmembrane and cytoplasmic tyrosine kinase (TK) domains play a vital role in cancer progression. Receptor tyrosine kinases (RTKs) are crucial intermediaries of the several cellular pathways and carcinogenesis that directly affect the prognosis and survival of higher tumor grade patients. Tyrosine kinase inhibitors (TKIs) are efficacious drugs for targeted therapy of various cancers. Therefore, RTKs have become a promising therapeutic target to cure cancer. A recent report shows that TKIs are vital mediators of signal transduction and cancer cell proliferation, angiogenesis, and apoptosis. In this review, we discuss the structure and function of RTKs to explore their prime role in cancer therapy. Various TKIs have been developed to date that contribute a lot to treating several types of cancer. These TKI based anticancer drug molecules are also discussed in detail, incorporating their therapeutic efficacy, mechanism of action, and side effects. Additionally, this article focuses on TKIs which are running in the clinical trial and pre-clinical studies. Further, to gain insight into the pathophysiological mechanism of TKIs, we also reviewed the impact of RTK resistance on TKI clinical drugs along with their mechanistic acquired resistance in different cancer types.Raj Kumar MongreChandra Bhushan MishraArvind Kumar ShuklaAmresh PrakashSamil JungMd Ashraf-Uz-ZamanMyeong-Sok LeeMDPI AGarticlereceptor tyrosine kinasesdrug resistancetargeted therapycancermutationclinical trialsBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 11659, p 11659 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	receptor tyrosine kinases drug resistance targeted therapy cancer mutation clinical trials Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	receptor tyrosine kinases drug resistance targeted therapy cancer mutation clinical trials Biology (General) QH301-705.5 Chemistry QD1-999 Raj Kumar Mongre Chandra Bhushan Mishra Arvind Kumar Shukla Amresh Prakash Samil Jung Md Ashraf-Uz-Zaman Myeong-Sok Lee Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?
description	GLOBOCAN 2020 estimated more than 19.3 million new cases, and about 10 million patients were deceased from cancer in 2020. Clinical manifestations showed that several growth factor receptors consisting of transmembrane and cytoplasmic tyrosine kinase (TK) domains play a vital role in cancer progression. Receptor tyrosine kinases (RTKs) are crucial intermediaries of the several cellular pathways and carcinogenesis that directly affect the prognosis and survival of higher tumor grade patients. Tyrosine kinase inhibitors (TKIs) are efficacious drugs for targeted therapy of various cancers. Therefore, RTKs have become a promising therapeutic target to cure cancer. A recent report shows that TKIs are vital mediators of signal transduction and cancer cell proliferation, angiogenesis, and apoptosis. In this review, we discuss the structure and function of RTKs to explore their prime role in cancer therapy. Various TKIs have been developed to date that contribute a lot to treating several types of cancer. These TKI based anticancer drug molecules are also discussed in detail, incorporating their therapeutic efficacy, mechanism of action, and side effects. Additionally, this article focuses on TKIs which are running in the clinical trial and pre-clinical studies. Further, to gain insight into the pathophysiological mechanism of TKIs, we also reviewed the impact of RTK resistance on TKI clinical drugs along with their mechanistic acquired resistance in different cancer types.
format	article
author	Raj Kumar Mongre Chandra Bhushan Mishra Arvind Kumar Shukla Amresh Prakash Samil Jung Md Ashraf-Uz-Zaman Myeong-Sok Lee
author_facet	Raj Kumar Mongre Chandra Bhushan Mishra Arvind Kumar Shukla Amresh Prakash Samil Jung Md Ashraf-Uz-Zaman Myeong-Sok Lee
author_sort	Raj Kumar Mongre
title	Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?
title_short	Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?
title_full	Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?
title_fullStr	Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?
title_full_unstemmed	Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?
title_sort	emerging importance of tyrosine kinase inhibitors against cancer: quo vadis to cure?
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/f7e4e2d1c4f14ffe8d65c0a026304786
work_keys_str_mv	AT rajkumarmongre emergingimportanceoftyrosinekinaseinhibitorsagainstcancerquovadistocure AT chandrabhushanmishra emergingimportanceoftyrosinekinaseinhibitorsagainstcancerquovadistocure AT arvindkumarshukla emergingimportanceoftyrosinekinaseinhibitorsagainstcancerquovadistocure AT amreshprakash emergingimportanceoftyrosinekinaseinhibitorsagainstcancerquovadistocure AT samiljung emergingimportanceoftyrosinekinaseinhibitorsagainstcancerquovadistocure AT mdashrafuzzaman emergingimportanceoftyrosinekinaseinhibitorsagainstcancerquovadistocure AT myeongsoklee emergingimportanceoftyrosinekinaseinhibitorsagainstcancerquovadistocure
_version_	1718432215947280384

Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?

Ejemplares similares